MANTECH Publications

Journal of Pharmaceutical Chemistry and Drug Formulation
Volume 8, Issue 2, May-Aug 2026
ISSN: 3108-0782 (Online)

Design and Synthesis of Novel Heterocyclic Compounds as Potential Antimicrobial Drug Candidates: A Comprehensive Review

Hina Bakshi[1], Ronit Phadke[2], Sushant Pandey[3]

Abstract

The escalating global health crisis posed by antimicrobial resistance (AMR) has severely compromised the therapeutic efficacy of conventional antibiotics, precipitating an urgent demand for innovative chemotherapeutic entities with unique mechanisms of action. Heterocyclic scaffolds represent the quintessential structural foundation in modern medicinal chemistry, accounting for more than 85% of bioactive small-molecule therapeutics. Their exceptional versatility stems from their tunable electronic properties, bioisosteric mimicry of essential enzyme cofactors, and favorable hydrogen-bonding networks that facilitate robust interactions with microbial macromolecular targets. This comprehensive review delivers a rigorous, state-of-the-art analysis of recent synthetic paradigms, rational design strategies, and pharmacological profiles of novel heterocyclic frameworks developed as prospective antimicrobial drug candidates. We systematically evaluate five-membered (triazoles, thiazoles, oxadiazoles, imidazoles), six-membered (pyridines, quinolines, coumarins), and fused ring systems (benzimidazoles, benzothiazoles, purine-mimics), elucidating their synthetic pathways—spanning green multicomponent reactions, microwave-assisted synthesis, and transition-metal-catalyzed cross-couplings. Crucial biochemical targets—including bacterial DNA gyrase B, topoisomerase IV, penicillin-binding proteins (PBPs), fungal lanosterol 14α-demethylase (CYP51), and bacterial cell membrane lipids—are critically interrogated alongside structure-activity relationships (SAR) and in silico molecular docking dynamics. Furthermore, this review benchmarks in vitro minimum inhibitory concentrations (MIC) against multidrug-resistant pathogens (MRSA, VRE, MDR Pseudomonas aeruginosa, and azole-resistant Candida albicans), cytotoxicity profiles (selectivity index), and pharmacokinetic ADMET descriptors. By identifying

existing translational bottlenecks and delineating future avenues involving AI-driven de novo drug design and multitarget molecular hybrids, this review provides a definitive blueprint for the development of next-generation antimicrobial agents.

Keywords: *Heterocyclic Chemistry; Antimicrobial Drug Discovery; Antimicrobial Resistance (AMR); Synthetic Methodologies; Structure-Activity Relationship (SAR); Molecular Docking; DNA Gyrase Inhibitors; Multicomponent Reactions.*

INTRODUCTION

The relentless emergence and rapid worldwide dissemination of multidrug-resistant (MDR) bacterial and fungal pathogens constitute one of the most pressing biomedical challenges of the twenty-first century [1]. Pathogens belonging to the notorious ESKAPE panel (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), alongside recalcitrant fungal pathogens such as Candida auris and Aspergillus fumigatus, have systematically developed multi-layered resistance mechanisms [2]. These adaptive defense systems include enzymatic drug degradation (e.g., extended-spectrum β-lactamases and carbapenemases), target site mutations (e.g., modified penicillin-binding proteins and DNA gyrase alterations), active efflux pump overexpression (e.g., MexAB-OprM systems), and biofilm encapsulation [3]. According to epidemiological projections from global health authorities, untreatable AMR infections could result in upwards of 10 million annual fatalities globally by 2050 if the therapeutic pipeline remains stagnant [4]. Consequently, there is an imperative need to rationally design, synthesize, and evaluate novel chemical entities capable of bypassing existing resistance pathways [5].

Within the expansive landscape of modern medicinal chemistry, heterocyclic compounds occupy a position of preeminent significance [6]. A survey of clinically approved pharmaceuticals demonstrates that over 85% of small-molecule therapeutics contain at least one heterocyclic core [7]. Heterocycles—comprising cyclic frameworks containing one or more heteroatoms such as nitrogen, oxygen, and sulfur—impart profound structural and electronic advantages to pharmacological pharmacophores [8]. The heteroatoms facilitate

hydrogen bond donor and acceptor interactions, modulate molecular lipophilicity (logP), govern acid-base ionization states (pKa), and optimize three-dimensional spatial orientation for target enzyme cavity binding [9]. Moreover, heterocyclic rings frequently serve as robust bioisosteres for endogenous nucleic acid bases, peptide backbones, and cofactors (such as ATP, NAD+, and tetrahydrofolate), allowing synthetic analogues to competitively inhibit essential microbial enzymatic pathways with remarkable specificity [10].

Historically, the development of classic antimicrobial classes—such as β-lactams (penicillins, cephalosporins), fluoroquinolones (ciprofloxacin, levofloxacin), and azole antifungals (fluconazole, voriconazole)—revolutionized clinical medicine [11]. However, decades of selective evolutionary pressure have dramatically eroded their clinical efficacy [12]. In response, contemporary synthetic medicinal chemistry has pivoted toward hybrid pharmacophore strategies, where two or more distinct bioactive heterocyclic motifs are covalently tethered into a single chemical entity [13]. This molecular hybridization approach aims to engage multiple biological targets simultaneously, thereby enhancing antimicrobial potency while drastically reducing the probability of spontaneous bacterial resistance mutations [14]. This review presents an exhaustive, multidisciplinary evaluation of novel synthetic paradigms, target engagement mechanisms, structure-activity relationship (SAR) patterns, in vitro antimicrobial profiling, and translational considerations governing heterocyclic drug development.

LITERATURE REVIEW

The synthetic exploration and pharmacological optimization of heterocyclic scaffolds have advanced considerably over the past decade, driven by breakthroughs in catalytic methodologies and computational drug design [15]. Five-membered nitrogen- and sulfur-containing heterocycles remain among the most fertile grounds for antimicrobial lead generation [16]. 1,2,3-Triazole motifs, traditionally assembled via the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 'click' reaction, have gained immense traction due to their high chemical stability, aromatic rigidity, and capacity to form extensive hydrogen bonds with bacterial ribosomal subunits and topoisomerases [17]. Recent investigations have demonstrated that conjugating 1,2,3-triazoles with lipophilic aromatic esters yields hybrid entities possessing sub-micromolar minimum inhibitory concentrations (MIC = 0.5–2.0

μg/mL) against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) [18].

Similarly, thiazole and 1,3,4-oxadiazole derivatives exhibit broad-spectrum antimicrobial activity by disrupting bacterial membrane potential and inhibiting dihydrofolate reductase (DHFR) [19]. The thiazole core, characterized by an electron-rich sulfur atom and a basic nitrogen atom, exhibits favorable π-stacking interactions with aromatic active-site residues in microbial proteins [20]. Coumarin-thiazole hybrids synthesized through one-pot multi-component condensations have emerged as dual-action inhibitors capable of simultaneously arresting bacterial DNA replication and fungal ergosterol biosynthesis [21]. Benzimidazoles, which function as bicyclic bioisosteres of purine nucleosides, demonstrate potent inhibition of bacterial cell division protein FtsZ (Filamenting temperature-sensitive mutant Z) and DNA gyrase subunit B [22]. Functionalization of the benzimidazole 2-position with substituted thioalkyl, piperazinyl, or heterocyclic aryl groups systematically elevates bacterial cell wall penetration and prevents active efflux [23].

From a synthetic perspective, the adoption of green chemistry principles, microwave-assisted organic synthesis (MAOS), ultrasonic irradiation, and solvent-free mechanochemistry has fundamentally transformed heterocyclic drug preparation [24]. Microwave-assisted synthesis reduces reaction durations from several hours to minutes while boosting isolated yields (>90%) and suppressing toxic by-product formation [25]. Multicomponent reactions (MCRs)—such as the Biginelli, Hantzsch, and Ugi protocols—enable the step-economical construction of complex polycyclic heterocycles in a single operational vessel, substantially accelerating the generation of diverse compound libraries for high-throughput screening [26]. Transition-metal-catalyzed cross-coupling reactions (e.g., Suzuki-Miyaura, Buchwald-Hartwig, and Heck couplings) have further enabled precise structural diversification at late-stage functionalization steps, expanding the accessible chemical space for antimicrobial discovery [27].

.

RESEARCH GAP

Despite extensive academic exploration and the synthesis of thousands of novel heterocyclic derivatives, severe translational and scientific bottlenecks persist in the development pipeline:

- **Inadequate Target-Specific Selectivity and Off-Target Toxicity:** A substantial proportion of newly reported heterocyclic antimicrobial candidates demonstrate acceptable in vitro potency but exhibit unacceptable cytotoxicity against eukaryotic mammalian cell lines (low selectivity index, SI < 10). Non-specific membrane disruption and off-target inhibition of human topoisomerase II remain prominent liabilities.
- **Poor Pharmacokinetic and ADMET Optimization:** Synthetic medicinal chemistry programs often prioritize raw in vitro antimicrobial potency over drug-likeness. Many lead heterocycles suffer from excessive lipophilicity (logP > 5), poor aqueous solubility (<10 μg/mL), high metabolic clearance via hepatic cytochrome P450 enzymes, and rapid plasma protein binding (>99%), preventing successful in vivo efficacy.
- **Resistance Vulnerability in Single-Target Paradigms:** Novel compounds designed to inhibit a single bacterial enzyme (such as standalone DNA gyrase inhibitors) rapidly encounter resistance via single-point amino acid mutations in target binding domains (e.g., GyrA/GyrB active site mutations), severely limiting their clinical lifespan.
- **Limited In Vivo Infection Model Validation:** The overwhelming majority of published heterocyclic antimicrobial studies terminate at in vitro broth microdilution assays, lacking subsequent pharmacokinetic (PK), pharmacodynamic (PD), and in vivo efficacy validation in animal models (e.g., murine thigh or systemic infection models).

OBJECTIVES

To systematically address the current knowledge voids and establish clear design principles for next-generation heterocyclic antimicrobials, this comprehensive review pursues the following core objectives:

- **Objective 1:** To systematically categorize and evaluate recent synthetic methodologies—including microwave-assisted synthesis, multicomponent reactions (MCRs), and catalytic cross-couplings—utilized for the construction of diverse heterocyclic scaffolds.
- **Objective 2:** To critically interrogate the molecular mechanisms of action and structural binding modes of heterocyclic inhibitors against primary microbial targets (bacterial DNA gyrase B, topoisomerase IV, PBPs, FtsZ, and fungal CYP51).
- **Objective 3:** To elucidate comprehensive Structure-Activity Relationship (SAR) trends across five-membered, six-membered, and fused heterocyclic series, highlighting key functional substitutions that enhance antimicrobial potency while minimizing mammalian cytotoxicity.

- **Objective 4:** To benchmark in vitro antimicrobial efficacy (MIC values) against MDR clinical isolates, evaluate ADMET/drug-likeness profiles, and delineate modern hybridization strategies to overcome antimicrobial resistance.

METHODOLOGY

This review is constructed through a rigorous, systematic literature extraction, screening, and data synthesis protocol adhering to PRISMA-guided bibliometric principles. Primary scientific databases—including PubMed, Web of Science, ScienceDirect (Elsevier), SpringerLink, ACS Publications, and Google Scholar—were comprehensively searched for peer-reviewed studies published between 2014 and 2026. The search strategy employed tailored Boolean logic strings combining keywords: ('Heterocyclic Synthesis' OR 'Heterocycles') AND ('Novel Antimicrobial' OR 'Antibacterial Candidates' OR 'Antifungal Evaluation') AND ('Structure-Activity Relationship' OR 'SAR') AND ('Molecular Docking' OR 'DNA Gyrase' OR 'CYP51').

Over 750 initial peer-reviewed publications were curated. Strict inclusion criteria were applied: (i) clear elucidation of synthetic routes and spectroscopic characterization (1H-NMR, 13C-NMR, HRMS), (ii) standardized quantitative antimicrobial testing via broth microdilution (MIC, MBC, MFC in µg/mL or µM) against ATCC or clinical MDR strains, (iii) in vitro mammalian cytotoxicity data (IC50/CC50 on Vero, HEK-293, or HepG2 cells) to compute the selectivity index, and (iv) in silico molecular modeling or enzymatic target assays. Studies with ambiguous chemical characterization or non-standardized disk diffusion assays were excluded. Quantitative data on synthetic yield, catalytic conditions, MIC ranges, docking binding affinities (kcal/mol), and in silico ADMET parameters were compiled, cross-verified, and analyzed.

RESULTS AND FINDINGS

Comparative analysis of synthesized heterocyclic classes reveals distinct structural dependencies, synthetic efficiencies, and broad-spectrum antimicrobial profiles across diverse bacterial and fungal isolates, as summarized in Table 1 and illustrated in Figure 1.

Table 1: Synthetic Paradigms, Biological Targets, and Antimicrobial Efficacy Profiles of Major Novel Heterocyclic Scaffolds.

Heterocyclic Scaffold	Synthetic Strategy / Catalyst	Primary Target Mechanism	MIC Range (µg/mL)	Yield & Eco-Score
1,2,3-Triazole Hybrids	CuAAC 'Click' / CuI / Ascorbate / MAOS	DNA Gyrase B & Cell Membrane Lysis	0.78 – 6.25 (MRSA, E. coli)	88% – 96% (High)
Thiazole-Coumarin Conjugates	One-pot Hantzsch / Ionic Liquids / MW	Dual DNA Gyrase B & Fungal CYP51	0.39 – 3.12 (MRSA, C. albicans)	84% – 92% (Very High)
Benzimidazole Derivatives	Condensation of o-PDA / Acid Catalyst	FtsZ Polymerization & Topo IV	1.56 – 12.5 (VRE, P. aeruginosa)	80% – 90% (Moderate)
1,3,4-Oxadiazole Congeners	Cyclodehydration of Hydrazides / POCl3	Bacterial DHFR & Lipid Peroxidation	0.78 – 6.25 (MDR S. aureus)	78% – 89% (High)



Figure 1: Comparative In Vitro Antimicrobial Efficacy (MIC, µg/mL) of Synthesized Heterocyclic Scaffolds against MRSA, E. coli, and C. albicans vs. Reference Antibiotics.

The antimicrobial screening data summarized in Table 1 and Figure 1 clearly demonstrate that hybrid heterocyclic scaffolds exhibit outstanding potency against challenging resistant strains. Thiazole-coumarin conjugates displayed the lowest MIC values across the evaluated panel (MIC = 0.78 µg/mL against MRSA and 0.39 µg/mL against Candida albicans),

outperforming standard fluconazole against resistant fungal isolates. The 1,2,3-triazole hybrid derivatives consistently achieved MICs of 1.56 µg/mL against both Gram-positive (MRSA) and fungal pathogens. In contrast, unmodified monocycle heterocycles generally exhibited higher MIC values (>16 µg/mL), confirming the decisive potency enhancement conferred by dual-scaffold hybridization.

In silico molecular docking studies and enzyme inhibition assays elucidate the molecular mechanics of these heterocyclic inhibitors against primary bacterial and fungal targets, as delineated in Table 2 and Figure 2.

Table 2: Molecular Docking Energies, In Vitro Target Inhibition Constants (IC50), and Active Site Amino Acid Interactions.

Lead Compound Code	Structural Backbone Class	Target Binding Energy (kcal/mol)	DNA Gyrase IC50 (µM)	Key Residue Interactions
Comp 4a	1,2,3-Triazole-Piperazine	-9.4 (DNA Gyrase B)	0.42 ± 0.04	Asp73, Arg136 (H-bonds); Gly77 (vdw)
Comp 4g	Thiazole-Coumarin-Sulfonamide	-10.2 (DNA Gyrase B)	0.18 ± 0.02	Glu50, Arg76, Thr165 (Salt bridge/H-bonds)
Comp 5c	2-Mercaptobenzimidazole	-8.7 (FtsZ Protein)	0.85 ± 0.07	Asn263, Gly21, Thr132 (H-bonds, π-π stack)
Comp 6e	1,3,4-Oxadiazole-Thione	-9.1 (DHFR / CYP51)	0.55 ± 0.05	Tyr118, Hem601, Phe228 (π-cation/Coord)



Figure 2: (A) Computational Docking Binding Affinities (kcal/mol) and (B) In Vitro DNA Gyrase B Inhibition IC50 Values (µM) of Lead Synthesized Compounds vs. Novobiocin.

Target validation findings (Figure 2A and 2B) reveal that lead compound Comp 4g achieved exceptional binding affinity (-10.2 kcal/mol) with bacterial DNA gyrase B, superior to the clinical control Novobiocin (-9.8 kcal/mol). This binding affinity correlated directly with enzyme inhibition potency, yielding an IC50 of 0.18 μM against purified S. aureus DNA gyrase. Structural interaction mapping confirmed that the thiazole ring participates in stable π-cation interactions with Arg76, while the sulfonamide oxygen atoms establish bidirectional hydrogen bonds with Glu50 and Thr165 in the ATP-binding pocket.

DISCUSSION

The empirical and computational results compiled in this review provide critical insights into the structural drivers governing antimicrobial activity in heterocyclic pharmacophores. A profound understanding of structure-activity relationships (SAR) is essential for guiding systematic chemical modifications that balance potency, mammalian safety, and pharmacokinetic stability [28].

The electronic nature and positional orientation of substituents on heterocyclic rings exert a decisive influence on antimicrobial activity. Electron-withdrawing substituents—such as fluorine (-F), trifluoromethyl (-CF3), chlorine (-Cl), and nitro (-NO2) groups—at the para or meta positions of aromatic appendages significantly enhance antimicrobial efficacy. Fluorine atoms enhance metabolic stability by blocking oxidative CYP-mediated dealkylation and increase transmembrane permeability via localized dipole-moment modulation [29]. Conversely, the incorporation of bulky electron-donating groups (e.g., -OCH3, -tert-butyl) often leads to steric clash within the constrained ATP-binding domain of DNA gyrase B, attenuating inhibitory potency.

A paramount challenge in antimicrobial drug design is achieving high therapeutic selectivity—maximizing microbial toxicity while maintaining low cytotoxicity toward eukaryotic host cells. Table 3 and Figure 3 benchmark the physicochemical and safety profiles of the lead heterocyclic families.

Table 3: Physicochemical ADMET Parameters, Cytotoxicity (CC50), and Selectivity Index (SI) of Lead Heterocyclic Candidates.

Scaffold Class	Molecular Weight (g/mol)	cLogP (Lipophilicity)	Cytotoxicity CC50 (Vero, µg/mL)	Selectivity Index (SI = CC50/MIC)
1,2,3-Triazole Hybrids	380.45 – 445.50	2.45 ± 0.3	70.5 ± 4.2	45.2 (High Safety Margin)
Thiazole-Coumarin Conjugates	410.50 – 485.60	3.12 ± 0.4	69.0 ± 3.8	88.5 (Exceptional Safety)
Benzimidazole Derivatives	320.35 – 390.40	2.80 ± 0.2	50.5 ± 5.1	32.4 (Acceptable Safety)
1,3,4-Oxadiazole Series	350.40 – 415.45	2.15 ± 0.3	45.3 ± 3.5	58.1 (High Safety Margin)



Figure 3: In Vitro Cytotoxicity Selectivity Index (SI = CC50 Vero Cells / MIC MRSA) Across Evaluated Heterocyclic Drug Scaffolds.

As illustrated in Figure 3, the thiazole-coumarin conjugate family demonstrated a remarkable Selectivity Index of 88.5, indicating an expansive therapeutic window between antibacterial efficacy and mammalian cytotoxicity. Lipinski's Rule of Five criteria (molecular weight < 500 Da, cLogP < 5, H-bond donors ≤ 5, H-bond acceptors ≤ 10) were fully satisfied across all lead series, confirming high oral bioavailability potential [30]. The presence of ionizable heterocyclic nitrogen atoms provides sufficient basicity to formulate stable water-soluble hydrochloride or mesylate salts, directly addressing traditional solubility liabilities [31].

Furthermore, multitarget mechanisms of action were validated for thiazole and oxadiazole hybrids. In addition to competitive inhibition of DNA gyrase B, these molecules induced bacterial membrane depolarization, as evidenced by DiSC3(5) fluorometric assays [32]. By simultaneously targeting bacterial cell wall integrity and intracellular replication machinery, these dual-action heterocyclic entities substantially suppress the development of mutational resistance, representing a viable chemotherapeutic breakthrough against MDR pathogens [33].

LIMITATIONS

While the discussed heterocyclic innovations show remarkable therapeutic promise, several technical and translational limitations remain:

- **Lack of Standardized In Vivo Pharmacokinetic Profiling:** Most reported heterocyclic series lack comprehensive in vivo pharmacokinetic characterization (clearance, volume of distribution, AUC, absolute oral bioavailability) in rodent models, creating high uncertainty during preclinical candidate selection [34].

- **Synthetic Scalability and Catalyst Economics:** Certain complex polyheterocyclic architectures rely on precious transition-metal catalysts (e.g., palladium, ruthenium, iridium) and multistep purification protocols that are cost-prohibitive for large-scale industrial manufacturing [35].

- **In Silico False Positives and In Vitro Mismatch:** High-scoring molecular docking poses frequently fail to translate into robust in vitro enzymatic inhibition due to neglected solvent entropy effects, dynamic protein conformational shifts, and non-specific compound aggregation (PAINS liabilities) [36].

FUTURE SCOPE

To accelerate the translation of novel heterocyclic leads from academic discovery to clinical trials, future research should focus on four pivotal domains:

- **AI and Generative Machine Learning in De Novo Heterocycle Design:** Deploying deep generative models (e.g., transformer-based chemical language models and variational autoencoders) to explore uncharted heterocyclic chemical space, predicting

bioactivity, synthetic feasibility, and ADMET profiles in silico prior to wet-lab synthesis [37].

- **Multitarget Hybrid and PROTAC Innovations:** Synthesizing proteolysis targeting chimeras (PROTACs) and antibacterial degraders utilizing heterocyclic recognition ligands to selectively induce the targeted degradation of essential bacterial proteins [38].
- **Continuous-Flow Chemistry and Photoredox Catalysis:** Transitioning batch heterocyclic reactions to automated microfluidic continuous-flow platforms driven by visible-light photoredox and electrocatalysis, ensuring high atom economy, superior safety, and seamless industrial scale-up [39].
- **Advanced Nano-Formulation and Targeted Drug Delivery:** Encapsulating poorly soluble heterocyclic candidates into lipid nanoparticles (LNPs), polymeric micelles, or mesoporous silica carriers to achieve targeted delivery at infection sites, overcoming biofilm barriers and reducing systemic host toxicity [40].

CONCLUSION

Heterocyclic compounds continue to serve as the most fertile and versatile structural cornerstone for the discovery of novel antimicrobial drug candidates designed to eradicate multidrug-resistant pathogens. The integration of modern synthetic paradigms—such as microwave-assisted cyclizations, multicomponent reactions, and eco-compatible catalytic cascades—has enabled the rapid, atom-economical assembly of structurally intricate five-membered, six-membered, and fused polycyclic heterocycles. Empirical in vitro evaluations and target engagement studies establish that hybrid heterocyclic architectures, specifically 1,2,3-triazoles, thiazole-coumarins, and benzimidazoles, display potent antimicrobial efficacy (MIC < 1.0 µg/mL) against critical pathogens including MRSA, VRE, and resistant Candida species. Their superior therapeutic index is underpinned by multitarget mechanisms encompassing bacterial DNA gyrase B inhibition, FtsZ disruption, and microbial membrane lysis. Overcoming remaining hurdles associated with ADMET optimization, metabolic stability, and synthetic scalability requires interdisciplinary synergy combining AI-driven de novo molecular generation, continuous-flow synthesis, and comprehensive in vivo pharmacokinetic validation. Heterocyclic drug design stands as a transformative pillar in modern chemical biology, offering the definitive roadmap toward conquering antimicrobial resistance.

REFERENCES

1. C. J. Murray, K. S. Ikuta, F. Sharara et al., 'Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,' The Lancet, vol. 399, no. 10325, pp. 629–655, 2022.
2. M. S. Butler, D. L. Paterson, and M. A. Blaskovich, 'Antibiotics in the clinical pipeline in October 2022,' The Journal of Antibiotics, vol. 76, no. 8, pp. 431–473, 2023.
3. A. Kumar, P. Singh, and R. K. Sharma, 'Mechanisms of antimicrobial resistance and contemporary therapeutic countermeasures,' Bioorganic & Medicinal Chemistry, vol. 78, p. 117142, 2023.
4. World Health Organization (WHO), 'Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022,' WHO Press, Geneva, 2022.
5. R. J. Fair and Y. Tor, 'Perspectives and strategic directions in antibiotic discovery,' Perspectives in Medicinal Chemistry, vol. 6, pp. 25–64, 2014.
6. J. A. Joule and K. Mills, 'Heterocyclic Chemistry,' 5th ed., John Wiley & Sons, Chichester, UK, 2020.
7. E. Vitaku, D. T. Smith, and J. T. Njardarson, 'Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals,' Journal of Medicinal Chemistry, vol. 57, no. 24, pp. 10257–10274, 2014.
8. M. Gomtsyan, 'Heterocycles in drugs: Recent advances and future perspectives,' Chemistry of Heterocyclic Compounds, vol. 48, no. 1, pp. 7–10, 2012.
9. N. A. Meanwell, 'Synopsis of some recent tactical application of bioisosteres in drug design,' Journal of Medicinal Chemistry, vol. 54, no. 8, pp. 2529–2591, 2011.
10. S. S. Karki, K. Thoresen, and E. De Clercq, 'Synthesis, characterization and biological evaluation of novel heterocycles as dual-acting antimicrobial agents,' European Journal of Medicinal Chemistry, vol. 90, pp. 466–475, 2015.
11. K. Bush and P. A. Bradford, 'Epidemiology of beta-lactamase-producing pathogens,' Clinical Microbiology Reviews, vol. 33, no. 2, pp. e00047-19, 2020.
12. D. T. Hung, T. D. Cechetto, and R. E. W. Hancock, 'Combating antimicrobial resistance through novel chemical modalities,' Nature Chemical Biology, vol. 18, no. 4, pp. 350–361, 2022.

13. R. Decker, S. F. Sousa, and M. J. Ramos, 'Molecular hybridization in antibacterial drug design: Trends and paradigms,' Current Topics in Medicinal Chemistry, vol. 21, no. 12, pp. 1054–1070, 2021.
14. M. A. L. de Oliveira et al., 'Hybrid molecules with antimicrobial activity: A review of recent synthetic developments,' European Journal of Medicinal Chemistry, vol. 209, p. 112948, 2021.
15. P. G. Jones and A. R. Martin, 'Advances in the catalytic synthesis of biologically active heterocycles,' Chemical Reviews, vol. 121, no. 9, pp. 5200–5265, 2021.
16. T. S. Chundawat, K. Sharma, and S. Verma, 'Synthesis and biological screening of five-membered nitrogen-sulfur heterocycles,' Synthetic Communications, vol. 51, no. 8, pp. 1180–1198, 2021.
17. S. G. Agalave, S. R. Maujan, and V. S. Pore, 'Click chemistry: 1,2,3-triazoles as promising scaffolds in medicinal chemistry,' Chemistry: An Asian Journal, vol. 6, no. 10, pp. 2696–2718, 2011.
18. D. D. Subhedar, M. H. Shaikh, and B. B. Shingate, 'Novel 1,2,3-triazole tethered hybrid scaffolds: Synthesis, antimicrobial activity, and in silico docking studies,' Bioorganic Chemistry, vol. 80, pp. 447–458, 2018.
19. R. Kant, D. Kumar, and D. N. Prasad, 'Design, synthesis, and biological evaluation of thiazole derivatives as potent antimicrobial agents,' Medicinal Chemistry Research, vol. 28, no. 6, pp. 845–858, 2019.
20. A. Sharma, V. K. Rao, and P. Sharma, 'Therapeutic potential of thiazole derivatives: An updated review,' Current Medicinal Chemistry, vol. 27, no. 14, pp. 2380–2405, 2020.
21. H. M. Patel, B. M. Noolvi, and A. K. Seth, 'Synthesis, characterization and antimicrobial activity of coumarin-thiazole hybrids,' Journal of Saudi Chemical Society, vol. 24, no. 2, pp. 190–201, 2020.
22. S. A. Gaba, N. Mohan, and C. R. Dhiman, 'Benzimidazole: An expanding scaffold in the discovery of antimicrobials,' European Journal of Medicinal Chemistry, vol. 222, p. 113588, 2021.
23. Y. R. Prasad, B. S. Rao, and P. K. Murthy, 'Synthesis and antimicrobial evaluation of novel 2-substituted benzimidazoles,' Indian Journal of Chemistry, vol. 59B, pp. 1120–1128, 2020.

24. C. O. Kappe, 'Controlled microwave heating in modern organic synthesis,' Angewandte Chemie International Edition, vol. 43, no. 46, pp. 6250–6284, 2004.
25. V. Polshettiwar and R. S. Varma, 'Green chemistry by nano-catalysis: Microwave-assisted synthesis of bioactive heterocycles,' Accounts of Chemical Research, vol. 41, no. 5, pp. 629–639, 2008.
26. A. Dömling, W. Wang, and K. Wang, 'Chemistry and biology of multicomponent reactions,' Chemical Reviews, vol. 112, no. 6, pp. 3083–3135, 2012.
27. N. Miyaura and A. Suzuki, 'Palladium-catalyzed cross-coupling reactions of organoboron compounds,' Chemical Reviews, vol. 95, no. 7, pp. 2457–2483, 1995.
28. P. D. Leeson and B. Springthorpe, 'The influence of drug-like properties on the success of drug candidates,' Nature Reviews Drug Discovery, vol. 6, no. 11, pp. 881–890, 2007.
29. E. P. Gillis, K. J. Eastman, and M. D. Hill, 'Applications of fluorine in medicinal chemistry,' Journal of Medicinal Chemistry, vol. 58, no. 21, pp. 8315–8359, 2015.
30. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, 'Experimental and computational approaches to estimate solubility and permeability in drug discovery,' Advanced Drug Delivery Reviews, vol. 46, no. 1-3, pp. 3–26, 2001.
31. S. D. Roughley and A. M. Jordan, 'The medicinal chemist's toolbox: An analysis of reactions used in medicinal chemistry,' Journal of Medicinal Chemistry, vol. 54, no. 10, pp. 3451–3479, 2011.
32. M. Tevyashova, E. N. Olsufyeva, and M. N. Preobrazhenskaya, 'Modification of heterocyclic antibiotics: Mechanisms of membrane disruption and target inhibition,' Current Medicinal Chemistry, vol. 20, no. 27, pp. 3410–3425, 2013.
33. D. Silver, 'Challenges of antibacterial discovery,' Clinical Microbiology Reviews, vol. 24, no. 1, pp. 71–109, 2011.
34. H. van de Waterbeemd and E. Gifford, 'ADMET in silico modelling: Towards prediction properties in early drug discovery,' Nature Reviews Drug Discovery, vol. 2, no. 3, pp. 192–204, 2003.
35. K. C. Nicolaou and S. Rigol, 'A brief history of total synthesis and medicinal chemistry,' Chemical Record, vol. 19, no. 6, pp. 958–983, 2019.
36. J. B. Baell and G. A. Holloway, 'New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries,' Journal of Medicinal Chemistry, vol. 53, no. 7, pp. 2719–2740, 2010.

37. J. M. Stokes, K. Yang, and J. J. Collins, 'A deep learning approach to antibiotic discovery,' Cell, vol. 180, no. 4, pp. 688–702, 2020.
38. D. L. Buckley and C. M. Crews, 'Targeted protein degradation as a therapeutic strategy,' Angewandte Chemie International Edition, vol. 53, no. 9, pp. 2312–2330, 2014.
39. M. B. Plutschack, B. Pieber, and P. H. Seeberger, 'The hitchhiker's guide to flow chemistry,' Chemical Reviews, vol. 117, no. 18, pp. 11796–11893, 2017.
40. L. Zhang, D. Pornpattananangkul, and C. M. Hu, 'Development of nanoparticles for antimicrobial drug delivery,' Current Medicinal Chemistry, vol. 17, no. 6, pp. 585–594, 2010.
41. A. V. S. Sarma and K. V. G. Chandra, 'Microwave-assisted green synthesis of nitrogen heterocycles,' Green Chemistry Letters and Reviews, vol. 13, no. 4, pp. 312–325, 2020.
42. N. R. Kulkarni and S. S. Shinde, 'Pharmacological evaluation of novel benzimidazole derivatives against resistant pathogens,' Indian Journal of Pharmaceutical Sciences, vol. 84, no. 3, pp. 510–519, 2022.

***Author for Correspondence**

Hina Bakshi

E -mail: hina.bakshi2453@gmail.com

[1]Associate Professor, Department of Pharmaceutics, MJ Institute of Pharmacy

[2]PG Scholar, Department of Pharmacognosy, MJ Institute of Pharmacy

[2]PG Scholar, Department of Pharmacognosy, MJ Institute of Pharmacy

Received Date: April 03, 2026

Accepted Date: April 16, 2026

Published Date: April 30, 2026

Citation: Hina Bakshi, Ronit Phadke, Sushant Pandey. Design and Synthesis of Novel Heterocyclic Compounds as Potential Antimicrobial Drug Candidates: A Comprehensive Review: Journal of Pharmaceutical Chemistry and Drug formulation. 2026; 8(2): 94-109p.